Replies to post #15704 on Mast Therapeutics, Inc. (MSTX)

[someconcerns]

Pray, Those are very old numbers for Savara. I have been a Savara shareholder since Series B in 2012 and I believe we've passed Series C as well. I just exercised my Series B warrants to buy more Savara shares at $3.13 in advance of the pending merger. This against a value at our last funding round of over $5/sh.

The pitchbook information also was back when Savara had 19 holders. I believe we are now much more broadly held: in the several hundreds. The Savara story (forgetting about MAST at the moment) has resonated well with investors.

Also holding a number of MSTX shares.